Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.760
-0.110 (-5.85%)
Dec 30, 2024, 1:05 PM EST - Market open
Inovio Pharmaceuticals Stock Forecast
INO's stock price has decreased by -71.08% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for INO stock have an average target of 16.33, with a low estimate of 5.00 and a high estimate of 40. The average target predicts an increase of 827.84% from the current stock price of 1.76.
Analyst Consensus: Buy
* Price targets were last updated on Nov 18, 2024.
Analyst Ratings
The average analyst rating for INO stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $12 → $5 | Hold | Maintains | $12 → $5 | +184.09% | Nov 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $33 → $15 | Buy | Maintains | $33 → $15 | +752.27% | Nov 18, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +240.91% | Nov 15, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +297.73% | Oct 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $40 → $33 | Buy | Maintains | $40 → $33 | +1,775.00% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
131.70K
from 832.01K
Decreased by -84.17%
Revenue Next Year
3.15M
from 131.70K
Increased by 2,290.97%
EPS This Year
-4.37
from -6.09
EPS Next Year
-3.22
from -4.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 210,000 | 16.0M | 61.6M | |||
| Avg | 131,704 | 3.1M | 27.4M | |||
| Low | 98,000 | n/a | 9.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -74.8% | 12,010.5% | 1,856.0% | |||
| Avg | -84.2% | 2,291.0% | 770.2% | |||
| Low | -88.2% | - | 209.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.29 | -2.15 | -1.31 | |||
| Avg | -4.37 | -3.22 | -2.10 | |||
| Low | -4.61 | -4.36 | -3.34 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.